The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy
Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
oral COX-2 inhibitor intake 60mg qd
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGProstaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO patients
measure the serum prostaglandin E2 level at 3 months
Time frame: 3 months
Prostaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO
measure the serum prostaglandin E2 level at 6 months
Time frame: 6 months
change in pain on VAS scale after COX-2 inhibitor treatment
use Visual Analogue Score (VAS) to evaluate pain
Time frame: 3 months
change in pain on VAS scale after COX-2 inhibitor treatment
Time frame: 6 months
change in pain on VAS scale after COX-2 inhibitor treatment
Time frame: 12 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
Time frame: 3 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
Time frame: 6 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 3 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 6 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 12 months